Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia
Salome Funes,Jonathan Jung,Del Hayden Gadd,Michelle Mosqueda,Jianjun Zhong,Shankaracharya,Matthew Unger,Karly Stallworth,Debra Cameron,Melissa S. Rotunno,Pepper Dawes,Megan Fowler-Magaw,Pamela J. Keagle,Justin A. McDonough,Sivakumar Boopathy,Miguel Sena-Esteves,Jeffrey A. Nickerson,Cathleen Lutz,William C. Skarnes,Elaine T. Lim,Dorothy P. Schafer,Francesca Massi,John E. Landers,Daryl A. Bosco
DOI: https://doi.org/10.1038/s41467-024-46695-w
IF: 16.6
2024-03-20
Nature Communications
Abstract:Abstract Microglia play a pivotal role in neurodegenerative disease pathogenesis, but the mechanisms underlying microglia dysfunction and toxicity remain to be elucidated. To investigate the effect of neurodegenerative disease-linked genes on the intrinsic properties of microglia, we studied microglia-like cells derived from human induced pluripotent stem cells (iPSCs), termed iMGs, harboring mutations in profilin-1 (PFN1) that are causative for amyotrophic lateral sclerosis (ALS). ALS-PFN1 iMGs exhibited evidence of lipid dysmetabolism, autophagy dysregulation and deficient phagocytosis, a canonical microglia function. Mutant PFN1 also displayed enhanced binding affinity for PI3P, a critical signaling molecule involved in autophagic and endocytic processing. Our cumulative data implicate a gain-of-toxic function for mutant PFN1 within the autophagic and endo-lysosomal pathways, as administration of rapamycin rescued phagocytic dysfunction in ALS-PFN1 iMGs. These outcomes demonstrate the utility of iMGs for neurodegenerative disease research and implicate microglial vesicular degradation pathways in the pathogenesis of these disorders.
multidisciplinary sciences